Peptide Atlas · Protein

Efinopegdutide

Efinopegdutide is a GLP-1 and glucagon receptor co-agonist given by subcutaneous injection once a week.

emerging

provisional
1 citation
0 discussions
0 followers
HM12525A
JNJ-64565111
LAPSGLP/GCG
MK-6024

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 1 citation resolves to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Efinopegdutide. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Efinopegdutide reduced liver fat content more than semaglutide over 24 weeks in NAFLD (phase IIa)	emerging	pmid 37355043

Unanswered questions

Have longer trials measured liver outcomes beyond fat content, such as fibrosis, with efinopegdutide? open

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.